Table 4.

P450 7B1

Properties	References
Physiological substrates: 25- and 27-Hydroxycholesterol, pregnenolone, dehydroepiandrosterone (DHEA), epiandrosterone, 5α-androstane-3β,17β-diol, estrone	(Rose et al. 1997; Steckelbroeck et al. 2002; Kim SB et al. 2004; Stiles et al. 2009; Yantsevich et al. 2014; Pan et al. 2016)
Function: 25-Hydroxycholesterol 7α-hydroxylase, oxysterol and steroid 6α- or 7α-hydroxylase (Fig. 6); involved in metabolism of neurosteroids (brain), bile acid synthesis (liver), and metabolism of estrogen receptor ligands (in prostate)
Inhibition: Possible liver failure and progressive neuropathy
Inhibitors:
Drugs:
Imidazole and triazole drugs (ketoconazole, bifoconazole, miconazole, clotrimazole, econazole, fluconazole, tioconazole, voriconazole) a (Kim SB et al. 2004; Yantsevich et al. 2014)
Metyrapone a (Yantsevich et al. 2014)
Physiological compounds:
5α-Androstane-3β,17β-diol, estrone, testosterone, 17β-estradiol b (Kim SB et al. 2004; Tang et al. 2006; Pettersson et al. 2008)
5α-Dihydrotestosterone b (at high concentrations) (Pettersson et al. 2008)
Estrogens (estrone, 17β-estradiol–in the absence of estrogen receptor α) b (Tang et al. 2006)
Triiodothyronine c (T3) (Ellis 2006)
β-Amyloid peptide (non-competitive inhibition) (Kim SB et al. 2004)
Physiological condition and illnesses:
Breast cancer d (Wu et al. 2013)
Prostatic cancer d (in type 2 diabetes) (Lutz et al. 2018)
Other compounds:
Pesticides a (tebuconazole, propiconazole) (Yantsevich et al. 2014)
Induction: Immunostimulatory effect of 7α-hydroxydehydroepiandosterone (used in rheumatoid artritis)
Inducers:
Drugs:
Rifampicin (Kim B et al. 2013)
Physiological compounds:
17β-Estradiol e (in human embryonic kidney (HEK293) cells transfected with estrogen receptor α) (Dulos, van der Vleuten, et al. 2005; Tang et al. 2006)
Interleukin-1 β interleukin-1α, interleukin-7, interleukin-17, activator protein-1, nuclear factor–κΒ, tumor necrosis factor-α e (Dulos, Kaptein, et al. 2005; Dulos, van der Vleuten, et al. 2005; Dulos and Boots 2006)
Physiological condition and illnesses:
Prostatic cancer f (Olsson et al. 2007)
Psoriasis f (Sumantran et al. 2016)
Other compounds:
Oleic acid anilide e (An et al. 2008)

Footnotes:

^aCompetitive inhibition, ligand binding

^bDecreased/suppressed/inhibited activity/product formation

^cReduced/suppressed mRNA and/or protein level/expression and activity

^dGene downregulated/suppressed

^eIncreased transcription/mRNA/protein expression/levels /and/or catalytic activity

^fUp-regulation of biosynthesis, increased expression of protein